Biomea Fusion, Inc. BMEA
We are a clinical‑stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases.
The company was founded in 2017 with the goal of creating targeted treatments built through expertise in chemistry and a deep understanding of metabolic biology. Following the strategic realignment announced in 2025, we now operate as an organization centered on two of our core drug candidate development programs: (i) icovamenib, our lead clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, our investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist (GLP-1 RA) in development for the treatment of obesity.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| R&D | $62.0M | $118.1M | $102.5M | $62.7M | $28.0M | $3.7M | $1.1M | — |
| SG&A | $19.3M | $26.0M | $23.6M | $20.9M | $13.7M | $1.7M | $103.0K | — |
| Total operating expenses | $83.5M | $144.1M | $126.1M | $83.6M | $41.7M | $5.3M | $1.2M | — |
| Operating income | -$83.5M | -$144.1M | -$126.1M | -$83.6M | -$41.7M | -$5.3M | -$1.2M | — |
| Interest expense | $1.9M | $5.6M | $8.9M | — | — | — | — | — |
| Pre-tax income | -$61.8M | -$138.4M | -$117.3M | -$81.8M | -$41.6M | -$5.3M | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | — | — |
| Net income | -$61.8M | -$138.4M | -$117.3M | -$81.8M | -$41.6M | -$5.3M | -$1.2M | — |
| EPS, basic | -1.18 | -3.83 | -3.44 | -2.80 | -1.74 | -0.51 | — | — |
| EPS, diluted | -1.18 | -3.83 | -3.44 | -2.80 | -1.74 | -0.51 | -0.20 | — |
| Shares, diluted (wtd. avg.) | 52.2M | 36.1M | 34.1M | 29.3M | 23.9M | 10.5M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $55.8M | $58.3M | $176.9M | $112.2M | $146.1M | $61.7M | $239.0K | $78.0K |
| Short-term investments | — | — | — | $1.1M | $27.8M | — | — | — |
| Total current assets | $58.0M | $68.3M | $179.2M | $117.8M | $176.6M | $62.2M | — | — |
| Property, plant and equipment | $153.0K | $3.8M | $5.2M | $5.8M | $3.0M | $81.0K | — | — |
| Total assets | $58.6M | $79.9M | $199.9M | $129.3M | $185.7M | $62.5M | — | — |
| Accounts payable | $3.2M | $12.9M | $6.9M | $6.8M | $1.3M | $727.0K | — | — |
| Total current liabilities | $11.1M | $21.7M | $22.9M | $19.1M | $4.6M | $1.6M | — | — |
| Total liabilities | $29.0M | $28.4M | $30.7M | $20.8M | $6.9M | $1.6M | — | — |
| Retained earnings | -$449.0M | -$387.3M | -$248.8M | -$131.6M | -$49.7M | -$8.2M | — | — |
| Total equity | $29.6M | $51.6M | $169.2M | $108.5M | $178.8M | $5.2M | -$21.0K | -$263.0K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$70.4M | -$119.9M | -$96.6M | -$62.4M | -$35.4M | -$4.5M | -$1.3M | — |
| Depreciation and amortisation | $1.4M | $1.7M | $1.5M | $691.0K | $249.0K | $8.0K | $0 | — |
| Stock-based compensation | $9.5M | $19.1M | $14.1M | $10.3M | $6.2M | $322.0K | — | — |
| Capital expenditure | — | $362.0K | $3.4M | $1.0M | $3.2M | $51.0K | — | — |
| Investing cash flow | — | -$362.0K | -$2.2M | $27.3M | -$33.4M | -$51.0K | — | — |
| Financing cash flow | $67.9M | $1.7M | $163.8M | $1.2M | $153.2M | $66.0M | $1.4M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-121825.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | — | -$1.2M | -$5.3M | -$41.6M | -$81.8M | -$117.3M | -$138.4M | -$61.8M |
Recent filings and events
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Results announced Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |